Eli Lilly’s blowout quarter should quiet investor concerns about the stock

Earnings

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 
George Frey | Bloomberg | Getty Images

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock.

Articles You May Like

Elon Musk endorses Trump’s transition co-chair Howard Lutnick for Treasury secretary
Target shares plunge 20% after discounter cuts forecast, posts biggest earnings miss in two years
How the world’s 431 women billionaires make, spend and give away their fortunes
Ex-Spousal Benefits: What ‘Independently Entitled’ Means
Thanksgiving meals are expected to be cheaper in 2024 as turkey prices drop

Leave a Reply

Your email address will not be published. Required fields are marked *